- Home
- VOR vs SGHT Comparison
VOR vs SGHT Comparison
Compare VOR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | SGHT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.1M | 395.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VOR | SGHT |
|---|---|---|
| Price | $12.06 | $5.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $64.78 | $8.23 |
| AVG Volume (30 Days) | ★ 956.5K | 290.5K |
| Earning Date | 03-19-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.62 | $2.03 |
| 52 Week High | $65.80 | $9.24 |
Technical Indicators
Market Signals| Indicator | VOR | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 31.19 |
| Support Level | $13.00 | $5.95 |
| Resistance Level | $15.00 | $6.59 |
| Average True Range (ATR) | 1.41 | 0.35 |
| MACD | -0.45 | -0.00 |
| Stochastic Oscillator | 8.68 | 2.36 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.